TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: total sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: serum urate-lowering efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of DIA
Endpoint domain: Adverse events/effects
Primary endpoint: DLRF scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average savings per hospital in patient care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Continence rate after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrepancies in ischemia and necrosis assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CIPN20 sensory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of STI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concentration of TNF‐α in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of sputum neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life as assessed by the St George's respiratory questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of gonorrhoea and chlamydia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consistent condom use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Levels of cholesterol (CH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: on-going pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: touch-evoked pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permanent stoma rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urgency/soiling subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bladder emptying performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity to detect CIN3 or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: speech outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confirmed occlusive event within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: detection to arrival time at a medical facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: personal accomplishment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: daily substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral change for chronic disease risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac death or recurrent hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of inadequate specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of postoperative IMU/ICU stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Living in own home at three months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Living in own home at six months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduced mortality in GEMU group
Endpoint domain: Mortality/survival
Primary endpoint: Mean clozapine AUC(0,infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean oral clearance of clozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratios between AUC(0, 12h) for desmethyl‐clozapine and AUC(0,12h) for clozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined endpoint of death, reinfarction, infarct‐related artery reocclusion, stroke or new‐onset heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative freedom from any atrial tachyarrhythmia at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of RBC DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-sensitivity C-reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rates of grade 4 or 5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Serum IgG HIV‐1‐specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IgG rabies and canarypox antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bleaching tolerability severity-days scores
Endpoint domain: Adverse events/effects
Primary endpoint: ROM measurement improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinesthesia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytomegalovirus retinitis control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median survival time after second implant
Endpoint domain: Mortality/survival
Primary endpoint: combined diagnostic and treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Short physical performance battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence from alcohol or other drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of HIV risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recidivism
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Postoperative hemoglobin decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Residual insulin leakage from the needle tip after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Anxiety Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visual analogue scale pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net peak external knee adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Uterine Volume (UV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glandular Myometrial Density (GMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory pure-tone thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of sutures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enamel shear bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberdeen LBP scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhea incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal toxicity (LENT-SOMA score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinical improvement in pain status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of postoperative sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring rescue analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Supervisor support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: postprandial triglyceride response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: shade change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mid-to-peripheral ACD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first heart failure hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Total cost of anesthesia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ultrasound energy consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days to cease diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: developmental delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hearing impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of SRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without vomiting/retching and rescue medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total response (no nausea, no vomiting/retching, and no use of rescue medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative overall incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of CD4 cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-8 to IL-10 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in condition-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Deficiencies in cognitive areas of non-verbal intelligence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: shorter morphine sulfate treatment days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 expression in peripheral blood monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Respiratory acquisition of ESBL‐producing K. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to wound healing
Endpoint domain: Resource use
Primary endpoint: Cost savings per successfully treated patient
Endpoint domain: Resource use
Primary endpoint: Prevalence of sexual activity postintervention
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: objective moderate-to-vigorous PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urinary free cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GFR prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Precision of GFR models
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: overnight fall in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CD8+/CD56+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Natural killer cell cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fatigue resolution time
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Muscle function decrement duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Memory Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: anti-protective antigen IgG geometric mean concentration (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of responders with a 4-fold rise in titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained corticosteroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rates (Crohn's Disease Activity Index score >220)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events leading to study drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in reflux episodes over 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of local SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction of hypochondriacal fears and beliefs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in affective disturbances
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in health care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bioavailability of nasally administered dihydroergotamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic indices (insulin, HOMA-IR, HOMA-B, QUICKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in balance function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revascularization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of symptomatic ICH
Endpoint domain: Adverse events/effects
Primary endpoint: Pain score on pack removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or MI occurring post PCI through 30-day follow-up
Endpoint domain: Mortality/survival
Primary endpoint: 3D skeletal growth directions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdialysis blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: locoregional recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of placing the coronary sinus catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean liver size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty infiltration status of the liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rates of H.pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sigmoidoscopic grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive-symptom score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 25-hydroxyvitamin D level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of repetitions of deliberate self poisoning
Endpoint domain: Mortality/survival
Primary endpoint: Detection of inflamed areas in the bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of FDG-PET analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of FDG-PET analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraoperative mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-h CrCl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fasting plasma glucose decreases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major hypoglycemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Time for first rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic efficacy (SPID value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with plasma HIV‐1 RNA < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakthrough fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Nephrotoxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Responder achieving a 30% or greater reduction from the baseline ICSI total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constriction of extracerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Constriction of cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of false alarms during the RVIP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of exudative subretinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCH thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in OHS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of patients treated with statins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite PAD z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain of 20% above body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMAP improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glottis visualization improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Easiness scores of laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median onset time for successful sciatic nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of sciatic nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in amplitude of action potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 2-year change in photographic breast appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: musculoskeletal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects with HBV DNA >3 log(10) c/mL at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early resistance development
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary artery occlusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: return to daily activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Seroprevalence of HHV-8 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Association between HHV-8 seropositivity and PCa risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean ventricular cycle lengths (AF CLmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes